Copyright © 2012 Jin-Lian Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

1. P. Carmeliet and R. K. Jain, “Angiogenesis in cancer and other diseases,” Nature, vol. 407, no. 6801, pp. 249–257, 2000. View at Publisher · View at Google Scholar · View at Scopus
2. P. H. Maxwell, G. U. Dachs, J. M. Gleadle et al., “Hypoxia-inducible factor-1 modulates gene expression in solid tumors and influences both angiogenesis and tumor growth,” Proceedings of the National Academy of Sciences of the United States of America, vol. 94, no. 15, pp. 8104–8109, 1997. View at Publisher · View at Google Scholar · View at Scopus
3. J. S. Mader, D. Smyth, J. Marshall, and D. W. Hoskin, “Bovine lactoferricin inhibits basic fibroblast growth factor- and vascular endothelial growth factor165-induced angiogenesis by competing for heparin-like binding sites on endothelial cells,” The American Journal of Pathology, vol. 169, no. 5, pp. 1753–1766, 2006. View at Publisher · View at Google Scholar · View at Scopus
4. H. J. Lee, E. O. Lee, Y. H. Rhee et al., “An oriental herbal cocktail, ka-mi-kae-kyuk-tang, exerts anti-cancer activities by targeting angiogenesis, apoptosis and metastasis,” Carcinogenesis, vol. 27, no. 12, pp. 2455–2463, 2006. View at Publisher · View at Google Scholar · View at Scopus
5. I. Vucenik, A. Passaniti, M. I. Vitolo, K. Tantivejkul, P. Eggleton, and A. M. Shamsuddin, “Anti-angiogenic activity of inositol hexaphosphate (IP6),” Carcinogenesis, vol. 25, no. 11, pp. 2115–2123, 2004. View at Publisher · View at Google Scholar · View at Scopus
6. H. Zhao, H. Liu, Y. Chen et al., “Oligomannurarate sulfate, a novel heparanase inhibitor simultaneously targeting basic fibroblast growth factor, combats tumor angiogenesis and metastasis,” Cancer Research, vol. 66, no. 17, pp. 8779–8787, 2006. View at Publisher · View at Google Scholar · View at Scopus
7. S. Javerzat, P. Auguste, and A. Bikfalvi, “The role of fibroblast growth factors in vascular development,” Trends in Molecular Medicine, vol. 8, no. 10, pp. 483–489, 2002. View at Publisher · View at Google Scholar · View at Scopus
8. D. Ribatti, “The crucial role of vascular permeability factor/vascular endothelial growth factor in angiogenesis: a historical review,” British Journal of Haematology, vol. 128, no. 3, pp. 303–309, 2005. View at Publisher · View at Google Scholar · View at Scopus
9. Y. D. Jung, P. F. Mansfield, M. Akagi et al., “Effects of combination anti-vascular endothelial growth factor receptor and anti-epidermal growth factor receptor therapies on the growth of gastric cancer in a nude mouse model,” European Journal of Cancer, vol. 38, no. 8, pp. 1133–1140, 2002. View at Publisher · View at Google Scholar · View at Scopus
10. N. Reinmuth, A. A. Parikh, S. A. Ahmad et al., “Biology of angiogenesis in tumors of the gastrointestinal tract,” Microscopy Research and Technique, vol. 60, no. 2, pp. 199–207, 2003. View at Publisher · View at Google Scholar · View at Scopus
11. A. Falanga and M. Marchetti, “Heparin in tumor progression and metastatic dissemination,” Seminars in Thrombosis and Hemostasis, vol. 33, no. 7, pp. 688–694, 2007. View at Publisher · View at Google Scholar · View at Scopus
12. J. L. Stevenson, A. Varki, and L. Borsig, “Heparin attenuates metastasis mainly due to inhibition of P- and L-selectin, but non-anticoagulant heparins can have additional effects,” Thrombosis Research, vol. 120, supplement 2, pp. S107–S111, 2007. View at Publisher · View at Google Scholar · View at Scopus
13. A. Naggi, B. Casu, M. Perez et al., “Modulation of the heparanase-inhibiting activity of heparin through selective desulfation, graded N-acetylation, and glycol splitting,” Journal of Biological Chemistry, vol. 280, no. 13, pp. 12103–12113, 2005. View at Publisher · View at Google Scholar · View at Scopus
14. J. L. Chen, W. X. Chen, J. S. Zhu et al., “Effect of P-selectin monoclonal antibody on metastasis of gastric cancer and immune function,” World Journal of Gastroenterology, vol. 9, no. 7, pp. 1607–1610, 2003. View at Scopus
15. S. A. Lang, D. Klein, C. Moser et al., “Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo,” Molecular Cancer Therapeutics, vol. 6, no. 3, pp. 1123–1132, 2007. View at Publisher · View at Google Scholar · View at Scopus
16. N. Wang, B. Wang, and Y. J. Wang, “Effect of vascular endothelial growth factor antibody Avastin on angiogenesis of human gastric cancer growing orthotopically in nude mice,” Ai Zheng, vol. 25, no. 9, pp. 1076–1081, 2006. View at Scopus
17. Y. L. Wu, S. L. Fu, Y. P. Zhang, M. M. Qiao, and Y. Chen, “Cyclooxygenase-2 inhibitors suppress angiogenesis and growth of gastric cancer xenografts,” Biomedicine and Pharmacotherapy, vol. 59, supplement 2, pp. S289–S292, 2005. View at Publisher · View at Google Scholar · View at Scopus
18. C. Pisano, C. Aulicino, L. Vesci et al., “Undersulfated, low-molecular-weight glycol-split heparin as an antiangiogenic VEGF antagonist,” Glycobiology, vol. 15, no. 2, pp. 1C–6C, 2005. View at Publisher · View at Google Scholar · View at Scopus
19. B. Casu, M. Guerrini, S. Guglieri et al., “Undersulfated and glycol-split heparins endowed with antiangiogenic activity,” Journal of Medicinal Chemistry, vol. 47, no. 4, pp. 838–848, 2004. View at Publisher · View at Google Scholar · View at Scopus
20. T. Zhou, J. L. Chen, W. Song et al., “Effect of N-desulfated heparin on hepatic/renal ischemia reperfusion injury in rats,” World Journal of Gastroenterology, vol. 8, no. 5, pp. 897–900, 2002. View at Scopus
21. D. Y. Lee, S. K. Kim, Y. S. Kim et al., “Suppression of angiogenesis and tumor growth by orally active deoxycholic acid-heparin conjugate,” Journal of Controlled Release, vol. 118, no. 3, pp. 310–317, 2007. View at Publisher · View at Google Scholar · View at Scopus
22. G. C. Jayson and J. T. Gallagher, “Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells,” British Journal of Cancer, vol. 75, no. 1, pp. 9–16, 1997. View at Scopus
23. K. Norrby, “2.5 kDa and 5.0 kDa heparin fragments specifically inhibit microvessel sprouting and network formation in VEFG₁₆₅-mediated mammalian angiogenesis,” International Journal of Experimental Pathology, vol. 81, no. 3, pp. 191–198, 2000. View at Scopus
24. K. Ono, M. Ishihara, K. Ishikawa et al., “Periodate-treated, non-anticoagulant heparin-carrying polystyrene (NAC-HCPS) affects angiogenesis and inhibits subcutaneous induced tumour growth and metastasis to the lung,” British Journal of Cancer, vol. 86, no. 11, pp. 1803–1812, 2002. View at Publisher · View at Google Scholar · View at Scopus
25. S. A. Mousa and S. Mohamed, “Anti-angiogenic mechanisms and efficacy of the low molecular weight heparin, tinzaparin: anti-cancer efficacy,” Oncology Reports, vol. 12, no. 4, pp. 683–688, 2004. View at Scopus
26. I. Vlodavsky, Z. Fuks, R. Ishai-Michaeli et al., “Extracellular matrix-resident basic fibroblast growth factor: implication for the control of angiogenesis,” Journal of Cellular Biochemistry, vol. 45, no. 2, pp. 167–176, 1991. View at Scopus
27. M. V. Cronauer, A. Hittmair, I. E. Eder et al., “Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate,” Prostate, vol. 31, Article ID 9180932, pp. 223–233, 1997.
28. A. Birck, A. F. Kirkin, J. Zeuthen, and K. Hou-Jensen, “Expression of basic fibroblast growth factor and vascular endothelial growth factor in primary and metastatic melanoma from the same patients,” Melanoma Research, vol. 9, no. 4, pp. 375–381, 1999. View at Scopus
29. M. R. Sartippour, L. Zhang, M. Lu, H. J. Wang, and M. N. Brooks, “Nipple fluid basic fibroblast growth factor in patients with breast cancer,” Cancer Epidemiology Biomarkers and Prevention, vol. 14, no. 12, pp. 2995–2998, 2005. View at Publisher · View at Google Scholar · View at Scopus
30. C. Barclay, A. W. Li, L. Geldenhuys et al., “Basic fibroblast growth factor (FGF-2) overexpression is a risk factor for esophageal cancer recurrence and reduced survival, which is ameliorated by coexpression of the FGF-2 antisense gene,” Clinical Cancer Research, vol. 11, no. 21, pp. 7683–7691, 2005. View at Publisher · View at Google Scholar · View at Scopus
31. M. Hatziapostolou, C. Polytarchou, P. Katsoris, J. Courty, and E. Papadimitriou, “Heparin affin regulatory peptide/pleiotrophin mediates fibroblast growth factor 2 stimulatory effects on human prostate cancer cells,” Journal of Biological Chemistry, vol. 281, no. 43, pp. 32217–32226, 2006. View at Publisher · View at Google Scholar · View at Scopus
32. O. E. Pardo, C. Wellbrock, U. K. Khanzada et al., “FGF-2 protects small cell lung cancer cells from apoptosis through a complex involving PKCε, B-Raf and S6K2,” EMBO Journal, vol. 25, no. 13, pp. 3078–3088, 2006. View at Publisher · View at Google Scholar · View at Scopus
33. J. Zhao, X. Y. Liu, Q. Y. Zhang, and W. Jiang, “Plasma level and prognostic significance of VEGF, bFGF and MMP-9 in patients with advanced non-small-cell lung cancer,” Zhonghua Zhong Liu Za Zhi, vol. 27, no. 11, pp. 676–679, 2005. View at Scopus
34. K. Yonemaru, H. Sakai, M. Murakami, T. Yanai, and T. Masegi, “Expression of vascular endothelial growth factor, basic fibroblast growth factor, and their receptors (flt-1, flk-1, and flg-1) in canine vascular tumors,” Veterinary Pathology, vol. 43, no. 6, pp. 971–980, 2006. View at Publisher · View at Google Scholar · View at Scopus